Products for Research Use Only
RegisterLogin

ML604440

CAT: 0804-HY-114170-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114170-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ML604440 is a specific and cell-permeable Proteasome β1i (LMP2) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor[1][2][3].
CAS Number
1140517-08-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Proteasome
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ml604440.html
Concentration
10mM
Purity
98.28
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)C[C@@H](B(O)O)NC(C(NC(C1=CC=CC=C1C(F)(F)F)=O)(C)C)=O
Molecular Formula
C17H24BF3N2O4
Molecular Weight
388.19
Precautions
H302, H315, H319
References & Citations
[1]de Bruin G, et al. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem. 2014 Jul 24;57 (14) :6197-209|[2]Basler M, et al. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep. 2018 Dec;19 (12) . pii: e46512.|[3]Sheng-Hong Du, et al. Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia. Front Immunol. 2021 Jan 20;11:603278.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
T12079-01ML604440
A18826-100ML604440 100mg
A18826-50ML604440 50mg
A18826-25ML604440 25mg
A18826-10ML604440 10mg
A18826-5ML604440 5mg
A18826-1ML604440 1mg
A18826-10mM-DML604440 10mM * 1mL in DMSO

Popular Products